Home
About Us
New Patients
Resources
Financial
Other Resources
GLI Resources
Experienced Patients
Active Clinical Trials
Research Findings
Immunology
Oncology
Treatment Management
Practice Guidelines
Understanding Lab Work
Medication Guides
Clinicians
Practice Guidelines
CME
Funding
Research Findings
Immunology
Oncology
Contact
Home
About Us
New Patients
Resources
Financial
Other Resources
GLI Resources
Experienced Patients
Active Clinical Trials
Research Findings
Immunology
Oncology
Treatment Management
Practice Guidelines
Understanding Lab Work
Medication Guides
Clinicians
Practice Guidelines
CME
Funding
Research Findings
Immunology
Oncology
Contact
Follow
Follow
Follow
Follow
TriSalus developing novel therapeutic solutions for liver and pancreatic tumors
Jan 9, 2024
|
Oncology
TriSalus Life Sciences (NASDAQ:TLSI) is addressing the mechanical and biologic barriers, such as high intratumoral pressure, within the tumor microenvironment (TME) that make it challenging to successfully treat liver and pancreatic tumors.
Learn More
Archives
March 2024
February 2024
January 2024
November 2023
October 2023
April 2023
January 2023
April 2022
October 2021
September 2021
July 2021
June 2021
January 2021
May 2020
January 2020
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer
Immune evasion tactics of liver cancer cells revealed
Finding the Right Targets to Treat Biliary Tract Cancers
Liver Cancer: A Promising Avenue for More Effective Immunotherapies
IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
Please ensure Javascript is enabled for purposes of
website accessibility